Medicinova (MNOV) Common Equity (2010 - 2025)

Medicinova (MNOV) has 16 years of Common Equity data on file, last reported at $41.6 million in Q4 2025.

• On a quarterly basis, Common Equity fell 20.79% year-over-year to $41.6 million in Q4 2025; TTM through Dec 2025 was $41.6 million, a 20.79% decrease from a year earlier, with the FY2025 full-year figure at $41.6 million, down 20.79% from the prior year.
• Common Equity for Q4 2025 stood at $41.6 million, down from $44.0 million in the prior quarter.
• Over the last five years, Common Equity for MNOV reached as high as $92.4 million in Q1 2021 and fell as low as $41.6 million in Q4 2025.
• Historically, Common Equity has averaged $66.0 million across 5 years, with a median of $64.9 million in 2023.
• Across the five-year window, Common Equity rose 26.2% in 2021 and decreased 20.79% in 2025, its largest moves.
• Year by year, Common Equity stood at $83.7 million in 2021, then retreated by 16.06% to $70.2 million in 2022, then slipped by 11.2% to $62.4 million in 2023, then dropped by 15.83% to $52.5 million in 2024, then decreased by 20.79% to $41.6 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $41.6 million in Q4 2025, $44.0 million in Q3 2025, and $46.9 million in Q2 2025.